Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
QuintilesIMS
Deloitte
Merck
Federal Trade Commission
Chubb

Generated: September 23, 2019

DrugPatentWatch Database Preview

Patent: 8,980,248

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,980,248
Title:Injectable polymer composition for use as a cell delivery vehicle
Abstract: This invention provides a polymer composition comprising at least one thermal gelling polymer and at least one anionic polymer for cell delivery applications. These injectable polymer compositions are shear-thinning, thixotropic and resorbable. More specifically there is described a hyaluronan (HA) and methylcellulose (MC) based thermogelling cell delivery system (HAMC) that promotes cell survival both in vitro and in vivo. Importantly, HAMC (relative to media alone) enhances survival of transplanted stem/progenitor cells in the injured CNS. HAMC provides a minimally-invasive cell delivery strategy where the microenvironment can be further defined and the differentiation and regenerative capacity further explored. This hydrogel system has applications for minimally-invasive cell delivery to other tissues/organs in the body as well.
Inventor(s): Shoichet; Molly Sandra (Toronto, CA), Zahir; Tasneem (Mississauga, CA), Ballios; Brian (Mississauga, CA), Van der Kooy; Derek (Toronto, CA), Cooke; Michael (Toronto, CA)
Assignee: The Governing Council of the University of Toronto (Toronto, Ontario, CA)
Application Number:13/516,846
Patent Claims:see list of patent claims

Details for Patent 8,980,248

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26 ➤ Sign Up The Governing Council of the University of Toronto (Toronto, Ontario, CA) 2029-12-18 RX search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26 ➤ Sign Up The Governing Council of the University of Toronto (Toronto, Ontario, CA) 2029-12-18 RX search
Genentech LUCENTIS ranibizumab INJECTABLE; INJECTION 125156 001 2006-06-30 ➤ Sign Up The Governing Council of the University of Toronto (Toronto, Ontario, CA) 2029-12-18 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Julphar
Fuji
Express Scripts
Chinese Patent Office
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.